FDA Chief Scott Gottlieb to Resign

Before becoming FDA commissioner, Gottlieb worked in the health care and pharmaceutical industries, and served on the board of a company that sold vaping products.

In a statement, Health and Human Services Secretary Alex Azar said Gottlieb was "an exemplary public health leader, aggressive advocate for American patients, and passionate promoter of innovation".

In an administration full of controversial agency heads, Gottlieb has earned bipartisan praise - even from Democrats, who were initially skeptical of the nomination given his past work for drug firms - for the FDA's efforts to speed the approval of generic treatments and reduce the use of e-cigarettes among the nation's youth, among other iniatives.

The FDA did not respond to a request for comment.

The 46-year-old millionaire physician, who has survived Hodgkin's lymphoma, said he wants to spend more time with his wife and three young daughters - a nine-year-old and twin five-year-olds - at their home in CT, rather than constantly commuting to Washington, DC.

Body of missing Sydney dentist Preethi Reddy found in suitcase
The man is believed to be her former boyfriend who was also attending the dental conference, a police source told AAP. A Facebook page was set up soon after Dr Reddy went missing, calling for people to " help find Preethi Reddy ".

Scott Gottlieb, who has flitted between government and Big Pharma, took the helm of the FDA in May 2017. He and his talents will be greatly missed!'

In September, Gottlieb called teen vaping an "epidemic" and vowed to crack down on companies that market to minors.

The FDA also introduced stricter age-verification requirements for online sales of e-cigarettes. According to a report in the Washington Post, the physician notified the Trump administration earlier this morning that he would be leaving his post, effective in about a month. He surprised critics who anxious about his ties to the pharmaceutical industry by speaking out about rising drug prices and drug companies' tactics to keep competitors off the market. He often touted that the agency had approved more than 1,000 generic drugs as evidence that it was helping to curb prescription drug prices, a top priority of Trump's administration.

Despite being well-liked by President Trump, and having recently introduced a number of new initiatives and new staff, Dr Gottlieb today said he would not complete two years in the role. Similarly, shares of Amgen Inc erased their gains and Gilead Sciences Inc shares added to losses.

Recommended News

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.